Vahit Özmen1, Ajlan Atasoy2, Erhan Gökmen3, Mustafa Özdoğan4, Nilufer Güler5, Cihan Uras6, Engin Ok7, Orhan Demircan8, Abdurrahman Işıkkdoğan9, Neslihan Cabioğlu1, Fatma Şen10, Pınar Saip10. 1. Department of General Surgery, İstanbul University İstanbul School of Medicine, İstanbul, Turkey. 2. Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, İstanbul, Turkey. 3. Division of Medical Oncology, Department of Internal Medicine, Ege University School of Medicine, İzmir, Turkey. 4. Division of Medical Oncology, Department of Internal Medicine, Akdeniz University School of Medicine, Antalya, Turkey; Department of General Surgery, Acıbadem University, İstanbul, Turkey. 5. Division of Medical Oncology, Department of Internal Medicine, Hacettepe University Institute of Oncology, Ankara, Turkey. 6. Department of General Surgery, Acıbadem University, İstanbul, Turkey. 7. Department of General Surgery, Erciyes University School of Medicine, Kayseri, Turkey. 8. Department of General Surgery, Çukurova University School of Medicine, Adana, Turkey; Department of General Surgery, Acıbadem University, İstanbul, Turkey. 9. Division of Medical Oncology, Department of Internal Medicine, Dicle University School of Medicine, Diyarbakır, Turkey. 10. Department of Medicine, Division of Medical Oncology, İstanbul University Institute of Oncology, İstanbul, Turkey.
Abstract
OBJECTIVE: Breast cancer is the most common malignancy among Turkish women and the rate of early stage disease is increasing. The Oncotype DX 21-gene assay is predictive of distant recurrence in ER-positive, HER2-negative early breast cancer. We aimed to evaluate the correlations between Recurrence Score (RS) and routine risk factors. MATERIALS AND METHODS: Ten academic centers across Turkey participated in this prospective trial. Consecutive patients with breast cancer who had pT1-3, pN0-N1mic, ER-positive, and HER2-negative tumors were identified at tumor conferences. Both pre- and post-RS treatment decisions and physician perceptions were recorded on questionnaire forms. Correlations between RS and classic risk factors were evaluated using univariate and multivariate analyses. RESULTS: Ten centers enrolled a total of 165 patients. The median tumor size was 2 cm. Of the 165 patients, 57% had low RS, 35% had intermediate RS, and 8% had high RS, respectively. Multivariate analysis indicated that progesterone receptor (PR) and Ki67 scores were significantly related to RS. CONCLUSION: Oncotype DX Recurrence Score does not seem to have a significant correlation with the majority of classic risk factors, but it may have a correlation with PR score and Ki67 score.
OBJECTIVE:Breast cancer is the most common malignancy among Turkish women and the rate of early stage disease is increasing. The Oncotype DX 21-gene assay is predictive of distant recurrence in ER-positive, HER2-negative early breast cancer. We aimed to evaluate the correlations between Recurrence Score (RS) and routine risk factors. MATERIALS AND METHODS: Ten academic centers across Turkey participated in this prospective trial. Consecutive patients with breast cancer who had pT1-3, pN0-N1mic, ER-positive, and HER2-negative tumors were identified at tumor conferences. Both pre- and post-RS treatment decisions and physician perceptions were recorded on questionnaire forms. Correlations between RS and classic risk factors were evaluated using univariate and multivariate analyses. RESULTS: Ten centers enrolled a total of 165 patients. The median tumor size was 2 cm. Of the 165 patients, 57% had low RS, 35% had intermediate RS, and 8% had high RS, respectively. Multivariate analysis indicated that progesterone receptor (PR) and Ki67 scores were significantly related to RS. CONCLUSION: Oncotype DX Recurrence Score does not seem to have a significant correlation with the majority of classic risk factors, but it may have a correlation with PR score and Ki67 score.
Authors: A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn Journal: Ann Oncol Date: 2015-05-04 Impact factor: 32.976
Authors: Jennifer E Joh; Nicole N Esposito; John V Kiluk; Christine Laronga; M Catherine Lee; Loretta Loftus; Hatem Soliman; Judy C Boughey; Carol Reynolds; Thomas J Lawton; Peter I Acs; Lucio Gordan; Geza Acs Journal: Oncologist Date: 2011-10-20
Authors: Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast Journal: J Clin Oncol Date: 2007-10-22 Impact factor: 44.544
Authors: Molly E Klein; David J Dabbs; Yongli Shuai; Adam M Brufsky; Rachel Jankowitz; Shannon L Puhalla; Rohit Bhargava Journal: Mod Pathol Date: 2013-03-15 Impact factor: 7.842
Authors: A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn Journal: Ann Oncol Date: 2013-08-04 Impact factor: 32.976